Share
David P. Southwell
Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David P. Southwell as Chief Executive Officer.
Bringing more than 30 years of C-level biotechnology leadership, Mr. Southwell will guide Volastra as it advances its pipeline, including two novel clinical-stage KIF18A inhibitors.
Mr. Southwell has extensive experience in financial, operational, and strategic leadership within the biotechnology and pharmaceutical sectors. He most recently served as President and CEO of TScan Therapeutics, an immune-oncology company developing T-cell receptor-based therapies. Prior to that, he was President, CEO, and Board Member of Inotek Pharmaceuticals, where he led the company through its merger with Rocket Pharmaceuticals in early 2018.
His earlier executive roles include CFO of Human Genome Sciences during its acquisition by GlaxoSmithKline and Executive Vice President and CFO of Sepracor Inc., where he served for more than a decade.
In addition to his executive roles, Mr. Southwell has served on the Boards of several public and private life sciences companies and currently sits on the Boards of PTC Therapeutics and Rocket Pharmaceuticals.
Mr. Southwell succeeds Charles Hugh-Jones, who has served as Volastra’s CEO since its inception. The Board expressed its deep appreciation for Dr. Hugh-Jones’ leadership, vision, and significant contributions over the past five years. He will continue to advise the company in his new capacity.
